

B¹

1. (Twice amended) A mutated bacterium selected from the group consisting of *Salmonella* species *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *hadar*, *heidelberg*, *agona*, and *arizonae* that in its wild type form carries flagella, said mutated bacterium lacking at least one antigenic determinant of flagellin or flagella found in its wild type form.

2. (Twice amended) The bacterium according to claim 1, wherein said bacterium lacks at least one antigenic determinant of flagellin or flagella, due to a mutation in a gene of the flagellar biogenesis pathway.

C¹
B²

6. (Amended twice) The bacterium according to claim 1, having the same immunological characteristics as the bacterium strain that has been deposited with the Centraalbureau voor Schimmelcultures under accession-number CBS 108995.

Please add the following new claims:

R126
sub
C²

11 12. (New) A vaccine for the protection of a subject against Salmonellosis comprising an immunologically effective amount of a mutated bacterium selected from the group consisting of the *Salmonella* species *typhi* and *paratyphi A* and *B* that in its wildtype form carries flagella, said mutated bacterium lacking at least one antigenic determinant of flagellin or flagella found in its wildtype form, or an antigenic material thereof and a pharmaceutically acceptable carrier.

B³

15 13. (New) The vaccine according to claim 12, wherein the bacterium is in a live attenuated form.

16 14. (New) The vaccine according to claim 12, wherein the bacterium is inactivated.

sub
C³

17 15. (New) The vaccine according to claim 12, comprising an adjuvant.

18 16. (New) The vaccine according to claim 12, in a freeze-dried or spray-dried form.